UCB SA Total Assets
UCB SA total assets. Based on the latest financial reports, UCB SA (UCB) holds total assets worth €20.63 Billion EUR (≈ $24.12 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see UCB cash flow conversion for how efficiently the company converts equity into cash flow.
Total Assets of UCB SA (2000–2025)
Total assets of UCB SA from 2000 to 2025. This chart illustrates how UCB SA's total assets have evolved over time, based on quarterly financial data. See UCB SA (UCB) stock price for real-time trading data and today's change.
UCB SA - Asset Composition Analysis
UCB SA Total Assets Breakdown (December 2025)
UCB SA total assets breakdown as of December 2025. UCB SA's total assets of €20.63 Billion consist of 33.3% current assets and 66.7% non-current assets. Explore UCB working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 12.4% |
| Accounts Receivable | €1.79 Billion | 9.8% |
| Inventory | €1.50 Billion | 8.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.45 Billion | 19.0% |
| Goodwill | €5.09 Billion | 28.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how UCB SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: UCB SA's current assets represent 33.3% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 12.4% of total assets in 2025, up from 4.7% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, an increase from 4.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 28.0% of total assets.
UCB SA Competitors by Total Assets
Key competitors of UCB SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.50 Billion |
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
UCB SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.20 | 1.35 | 1.23 |
| Quick Ratio | 0.82 | 1.01 | 0.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €923.00 Million | €1.39 Billion | €555.00 Million |
UCB SA - Advanced Valuation Insights
This section examines the relationship between UCB SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.46 |
| Latest Market Cap to Assets Ratio | 2.12 |
| Asset Growth Rate (YoY) | 4.7% |
| Total Assets | €18.16 Billion |
| Market Capitalization | $38.48 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values UCB SA's assets at a significant premium (2.12x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: UCB SA's assets grew by 4.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for UCB SA (2000–2025)
The table below shows the annual total assets of UCB SA from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €18.16 Billion ≈ $21.23 Billion |
+4.68% |
| 2024-12-31 | €17.35 Billion ≈ $20.28 Billion |
+11.64% |
| 2023-12-31 | €15.54 Billion ≈ $18.17 Billion |
-2.07% |
| 2022-12-31 | €15.87 Billion ≈ $18.55 Billion |
+11.67% |
| 2021-12-31 | €14.21 Billion ≈ $16.61 Billion |
+6.69% |
| 2020-12-31 | €13.32 Billion ≈ $15.57 Billion |
+20.20% |
| 2019-12-31 | €11.08 Billion ≈ $12.95 Billion |
+5.39% |
| 2018-12-31 | €10.51 Billion ≈ $12.29 Billion |
+6.02% |
| 2017-12-31 | €9.92 Billion ≈ $11.59 Billion |
-2.89% |
| 2016-12-31 | €10.21 Billion ≈ $11.94 Billion |
-6.79% |
| 2015-12-31 | €10.96 Billion ≈ $12.81 Billion |
+7.96% |
| 2014-12-31 | €10.15 Billion ≈ $11.86 Billion |
+3.98% |
| 2013-12-31 | €9.76 Billion ≈ $11.41 Billion |
+4.27% |
| 2012-12-31 | €9.36 Billion ≈ $10.94 Billion |
+1.98% |
| 2011-12-31 | €9.18 Billion ≈ $10.73 Billion |
+2.33% |
| 2010-12-31 | €8.97 Billion ≈ $10.49 Billion |
-1.66% |
| 2009-12-31 | €9.12 Billion ≈ $10.66 Billion |
-4.24% |
| 2008-12-31 | €9.52 Billion ≈ $11.13 Billion |
-0.32% |
| 2007-12-31 | €9.55 Billion ≈ $11.17 Billion |
-8.98% |
| 2006-12-31 | €10.50 Billion ≈ $12.27 Billion |
+122.56% |
| 2005-12-31 | €4.72 Billion ≈ $5.51 Billion |
-12.22% |
| 2004-12-31 | €5.37 Billion ≈ $6.28 Billion |
+73.85% |
| 2003-12-31 | €3.09 Billion ≈ $3.61 Billion |
+17.93% |
| 2002-12-31 | €2.62 Billion ≈ $3.06 Billion |
+2.23% |
| 2001-12-31 | €2.56 Billion ≈ $3.00 Billion |
+11.32% |
| 2000-12-31 | €2.30 Billion ≈ $2.69 Billion |
-- |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more